Background Triple-negative breast cancer (TNBC) exhibits biologically aggressive behavior
and has a poor prognosis. Novel molecular targeting agents are needed to control TNBC. …

Estradiol (E2) increases not only the cell growth but also the cancer stem cell ( CSC ) proportion
in estrogen receptor ( ER )‐positive breast cancer cells. It has been suggested that the …

Although paclitaxel plus bevacizumab (PB) therapy is an effective chemotherapeutic regimen
for HER2-negative advanced breast cancer (ABC), predictive markers for its effectiveness …

Background/Aim: We investigated the usefulness of dynamic changes in absolute lymphocyte
count (ALC) and neutrophil-to-lymphocyte ratio (NLR) during eribulin therapy as predictive …

Background Although the poly adenosine diphosphate (ADP)-ribose polymerase (PARP)
inhibitor olaparib is known to have potent antitumor activity in BRCA-related breast cancer cells…

Background Eribulin mesylate (eribulin), a non-taxane microtubule dynamic inhibitor, has
been widely used in the treatment of patients with advanced or metastatic breast cancer. The …

Purpose Whether postoperative chemotherapy should be added to endocrine therapy or not
is an important issue in patients with hormone receptor-positive and human epidermal …

Background Next-generation sequencing (NGS) has shown that recurrent/metastatic breast
cancer lesions may have additional genetic changes compared with the primary tumor. …

Background Adjuvant trastuzumab has been routinely used in HER2-positive operable breast
cancer patients. Prognostic factors remain to be well characterized in these patients and …

Purpose Increased vascular access flow after percutaneous transluminal angioplasty (PTA)
for central venous stenosis and occlusion (central venous disease, CVD) can affect cardiac …